1-100 of 2,701 results for subject:MRSA
Librarians' tools
- Search time
- 0.788 seconds
- Solr query time
- 0.015 seconds
- Search query
- subject:MRSA
- We searched for
- subject_t:MRSA OR subject_t:"Methicillin resistant staphylococcus aureus" OR subject_ses:11632
Type
House
Session
Year
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Environment, Food and Rural Affairs, what steps he plans to take to take to ensure drinking water is not contaminated by antibiotic-resistant strains of E. coli and staphylococcus aureus.
To ask the Secretary of State for Environment, Food and Rural Affairs, what steps he plans to take to take to ensure drinking water is not contaminated by antibiotic-resistant strains of E. coli and staphylococcus aureus.
Drinking water in England is very high quality. The Drinking Water Inspectorate is the regulator for drinking water quality, which is regulated through the Water Supply (Water Quality) Regulations 2016. These include strict standards for microbiology to protect public health from pathogens, together with a general requirement for water to be wholesome. The safety of drinking water is confirmed through regular sampling programmes, and any breaches are investigated and enforcement action taken when necessary. Water companies adopt a water safety planning approach, in line with WHO advice. Risks are identified, reported to the Inspectorate, and mitigated before they lead to any deterioration in quality or impact on consumers
Drinking water is treated in England and disinfected to protect consumers. Disinfection is highly effective against viruses and bacteria, including E. coli and staphylococcus aureus, and is not affected by anti-microbial resistance, because it relies on a different inactivation process, either using chlorine or UV disinfection.
My Lords, I first thank the noble Baroness, Lady Greengross, and congratulate her on securing this debate on an incredibly important topic, which definitely performs above the graveyard slot it has been given on a Thursday afternoon. It has been a very useful and informative debate, and a good opportunity...
My Lords, I first thank the noble Baroness, Lady Greengross, and congratulate her on securing this debate on an incredibly important topic, which definitely performs above the graveyard slot it has been given on a Thursday afternoon. It has been a very useful and informative debate, and a good opportunity...
My Lords, I declare an interest as the CEO of the International Longevity Centre-UK, which has done quite a lot of work on the issues that we are discussing. Antimicrobial resistance poses an unprecedented threat to human health. As bacteria become resistant to antibiotics, even minor infections have the potential...
My Lords, I declare an interest as the CEO of the International Longevity Centre-UK, which has done quite a lot of work on the issues that we are discussing. Antimicrobial resistance poses an unprecedented threat to human health. As bacteria become resistant to antibiotics, even minor infections have the potential...
My Lords, I add my thanks to the noble Baroness, Lady Greengross, for introducing this debate on such an important matter.
The seriousness of this issue was stated starkly by the Chief Medical Officer, Professor Dame Sally Davies, who said that if we do not act, it is possible that we...
My Lords, I add my thanks to the noble Baroness, Lady Greengross, for introducing this debate on such an important matter.
The seriousness of this issue was stated starkly by the Chief Medical Officer, Professor Dame Sally Davies, who said that if we do not act, it is possible that we...
My Lords, I congratulate the noble Baroness on securing this debate on the risks of antimicrobial resistance, or AMR. Although it is last on the list of the short debates this afternoon, this debate follows quite nicely on from the debate we had on 22 November last year when we...
My Lords, I congratulate the noble Baroness on securing this debate on the risks of antimicrobial resistance, or AMR. Although it is last on the list of the short debates this afternoon, this debate follows quite nicely on from the debate we had on 22 November last year when we...
My Lords, I, too, thank the noble Baroness, Lady Greengross, for securing this extremely important and timely debate. I begin by declaring an interest as vice-chair of the APPG on Global Tuberculosis, and I refer noble Lords to my interests as set out in the register and my work with
notus-xml...
My Lords, I, too, thank the noble Baroness, Lady Greengross, for securing this extremely important and timely debate. I begin by declaring an interest as vice-chair of the APPG on Global Tuberculosis, and I refer noble Lords to my interests as set out in the register and my work with
notus-xml...
My Lords, I thank my noble friend Lady Greengross for securing this short debate. It may be short but it is of tremendous importance globally. AMR is widely recognised as the biggest threat we face.
Many years ago I was the first person in your Lordships’ House to have a debate...
My Lords, I thank my noble friend Lady Greengross for securing this short debate. It may be short but it is of tremendous importance globally. AMR is widely recognised as the biggest threat we face.
Many years ago I was the first person in your Lordships’ House to have a debate...
My Lords, it is a great pleasure to wind up for the Opposition and thank the noble Baroness, Lady Greengross, for an excellent contribution, which other noble Lords added
to. I want to raise two issues. One is about the use of antibiotics in animals and the other is about...
My Lords, it is a great pleasure to wind up for the Opposition and thank the noble Baroness, Lady Greengross, for an excellent contribution, which other noble Lords added
to. I want to raise two issues. One is about the use of antibiotics in animals and the other is about...
Lords question for short debate on what assessment they have made of the risks of antimicrobial resistance.
Lords question for short debate on what assessment they have made of the risks of antimicrobial resistance.
To ask the Secretary of State for Environment, Food and Rural Affairs, on what dates Ministers and officials in her Department met with (a) representatives from the British pork industry and (b) her EU counterparts to discuss the MRSA superbug strain.
To ask the Secretary of State for Environment, Food and Rural Affairs, on what dates Ministers and officials in her Department met with (a) representatives from the British pork industry and (b) her EU counterparts to discuss the MRSA superbug strain.
Government regularly meets with representatives from the British pork industry and EU counterparts to discuss a wide range of topics which can include MRSA.
Officials from the Veterinary Medicines Directorate, who are responsible for antibiotic resistance policy, have met twice this year with the British pork industry to specifically discuss the topic of Livestock Associated MRSA. The last meeting was on 11 October 2016.
To ask the Secretary of State for Health, how many hospital-borne cases of MRSA were recorded in England in (a) 2000, (b) 2005, (c) 2010 and (d) 2015.
To ask the Secretary of State for Health, how many hospital-borne cases of MRSA were recorded in England in (a) 2000, (b) 2005, (c) 2010 and (d) 2015.
In April 2013 Public Health England took over the surveillance of methicillin-resistant staphylococcus aureus (MRSA) bacteraemia, formerly undertaken by the Health Protection Agency. We do not hold the data for 2000 and 2005.
Cases are published according to both trust apportionment and trust assignment. For the purpose of answering this question trust apportionment or assignment can be considered as “hospital borne” cases.
The assignment process was added to the MRSA surveillance in 2013 superseding the previously used apportionment method. The assignment process utilises individual case review and therefore allows for a much more considered categorisation of a case and associated learning to prevent similar cases occurring in the future, than was previously possible. The assignment process was only introduced in 2013 as MRSA numbers were previously considered to be too high to make this resource demanding method viable.
The total number of trust apportioned and trust assigned cases are displayed in Tables 1 and 2 respectively.
Table 1: Trust apportioned counts of MRSA bacteraemia in 2008, 2010 and 2015.
April 2008 to March 2009 | April 2010 to March 2011 | April 2015 to March 2016 |
1,606 | 688 | 297 |
Table 2: Trust assigned counts of MRSA bacteraemia in 2015.
April 2015 to March 2016 |
302 |
Notes:
- Cases are published on a financial year basis.
- Trust apportioned data are not available for the years 2000 and 2005.
- Trust assigned are not available for the years 2000, 2005 and 2010.
- Cases are deemed to be Trust apportioned if the following criteria are met:-
- The location where the specimen was taken is given as ‘acute trust’ or is not known;
- The patient was either an ‘In-patient’, ‘Day-patient’, in ‘Emergency assessment’ or is not known.
- Patient’s specimen date is on, or after, the third day of the admission (or admission date is null), where the day of admission is day 1.
- Cases are deemed to be trust assigned on the basis of Post Infection Review (PIR) assignment and relevant cases are assigned to acute trusts.
- The trust assignment method supersedes the apportionment one post 2013 and utilises case review by the teams caring for the patient.
To ask the Secretary of State for Environment, Food and Rural Affairs, when the Government plans to undertake a national monitoring survey of the pig population for the presence of MRSA.
To ask the Secretary of State for Environment, Food and Rural Affairs, when the Government plans to undertake a national monitoring survey of the pig population for the presence of MRSA.
A UK-wide baseline survey to look for the presence of livestock associated meticillin resistant Staphylococcus aureus (LA-MRSA) in UK pigs was performed in 2008 in line with European Food Safety Authority (EFSA) protocols. At that point, none of the farms tested were found to be positive for MRSA. Since then, the organism has been detected in livestock in the UK. Current advice from the Food Standards Agency (FSA) and Public Health England (PHE) is that LA-MRSA poses a low risk to human health.
The people that are most likely to become colonised by LA-MRSA are those who work with livestock. Defra is therefore undertaking a study with Public Health England (PHE) to investigate the occurrence of LA-MRSA in veterinarians and livestock workers. The results of this study will be used to inform the need for future surveillance.
To ask the Secretary of State for Environment, Food and Rural Affairs, what assessment her Department has made of the prevalence of livestock-associated MRSA in live breeder pigs and meat products imported from (a) Denmark and (b) other European countries; what proportion of such imports are voluntarily tested for livestock-associated...
To ask the Secretary of State for Environment, Food and Rural Affairs, what assessment her Department has made of the prevalence of livestock-associated MRSA in live breeder pigs and meat products imported from (a) Denmark and (b) other European countries; what proportion of such imports are voluntarily tested for livestock-associated...
Livestock associated meticillin resistant Staphylococcus aureus (LA-MRSA) is not a notifiable organism. There is no mandatory requirement to test imports of live breeding pigs or pig meat for the presence of LA-MRSA.
The National Pig Association recommends in its Import Protocol that imported pigs be screened for the presence of MRSA. Such testing is done on a voluntary and private basis.
Any controls or testing introduced for an organism must be proportionate to the risk posed by it. Current advice from the Food Standards Agency (FSA) and Public Health England (PHE) is that LA-MRSA poses a low risk to human health.
To ask the Secretary of State for Business, Innovation and Skills, what engagement his Department has had with the Accelerated Access Review (AAR); and whether the AAR plans to investigate expediting the delivery of new drugs and devices to tackle MRSA and antimicrobial resistance.
To ask the Secretary of State for Business, Innovation and Skills, what engagement his Department has had with the Accelerated Access Review (AAR); and whether the AAR plans to investigate expediting the delivery of new drugs and devices to tackle MRSA and antimicrobial resistance.
The Accelerated Access Review team is a joint unit between the Department of Health and the Department for Business, Innovation and Skills. The Accelerated Access Review is intended to reform the landscape for the assessment, adoption and reimbursement of innovative drugs, devices and other treatments across all therapeutic areas.
To ask the Secretary of State for Health, what assessment his Department has made of the relationship between hand hygiene compliance levels across the NHS and rates of trust-assigned MRSA bacteraemia in 2015.
To ask the Secretary of State for Health, what assessment his Department has made of the relationship between hand hygiene compliance levels across the NHS and rates of trust-assigned MRSA bacteraemia in 2015.
As hand hygiene is known to be an important part of a robust approach to infection prevention and control the Department’s guidance to the National Health Service on infection prevention and control was strengthened last year. However, a national assessment for 2015 is not available as information on hand hygiene compliance is not collected centrally. Auditing of hand hygiene is a local responsibility.
Letter dated 04/02/2016 from Ben Gummer MP to Nigel Mills MP regarding the hand hygiene debate and rates of MRSA, MSSA, C. diff and E. coli. 1 p.
Letter dated 04/02/2016 from Ben Gummer MP to Nigel Mills MP regarding the hand hygiene debate and rates of MRSA, MSSA, C. diff and E. coli. 1 p.
To ask the Secretary of State for Health, if he will make a comparative assessment of the number of recorded MRSA infections recorded in (a) Sherwood Forest Hospitals NHS Foundation Trust, (b) Nottingham University Hospitals NHS Trust and (c) England in each of the last five years.
To ask the Secretary of State for Health, if he will make a comparative assessment of the number of recorded MRSA infections recorded in (a) Sherwood Forest Hospitals NHS Foundation Trust, (b) Nottingham University Hospitals NHS Trust and (c) England in each of the last five years.
The number of Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia reported by and attributed to Sherwood Forest Hospitals NHS Foundation Trust, Nottingham University Hospitals NHS Trust in the past seven financial years (FYs) is provided in the table below. Total MRSA reports and acute trust attribution is also provided for England.
MRSA bacteraemia reported by and attributed to Sherwood Forest Hospitals NHS Foundation Trust, Nottingham University Hospitals NHS Trust (FY 2008/09 to FY 2014/15)
Sherwood Forest | Nottingham University Hospitals | England | ||||
Reported | Trust apportioned | Reported | Trust apportioned | Reported | Trust apportioned | |
2008/09 | 31 | 17 | 35 | 17 | 2935 | 1606 |
2009/10 | 14 | 6 | 40 | 21 | 1898 | 1004 |
2010/11 | 6 | 0 | 11 | 5 | 1481 | 688 |
2011/12 | 3 | 0 | 14 | 8 | 1116 | 473 |
2012/13 | 1 | 0 | 13 | 5 | 924 | 398 |
2013/14 | 5 | 3 | 7 | 2 | 862 | 364 |
2014/15 | 5 | 0 | 11 | 4 | 801 | 287 |
Source:
- Annual results from the mandatory MRSA reporting scheme (FY 2007/08 to 2014/15).
This data is not case-mix adjusted (i.e. they do not take into account the different population types served by each hospital) and so are not directly comparable. It is important to note that MRSA bacteraemia cases are reported by the acute trust whose laboratory processes the specimen and this may not always reflect where the bacteraemia was acquired.
Public Health England is working, with partner organisations, to address antimicrobial resistance through the implementation of the UK Five Year Antimicrobial Resistance Strategy[1].
[1] https://www.gov.uk/government/publications/uk-5-year-antimicrobial resistance-strategy-2013-to-2018
To ask the Secretary of State for Health, if he will make a comparative assessment of the number of recorded MRSA infections in (a) Havering and (b) other districts in (i) the present and (ii) the last three years; and if he will make a statement.
To ask the Secretary of State for Health, if he will make a comparative assessment of the number of recorded MRSA infections in (a) Havering and (b) other districts in (i) the present and (ii) the last three years; and if he will make a statement.
Public Health England (PHE) is unable to provide the number of recorded Methicillin Resistant Staphylococcus Aureus (MRSA) infections by borough/district.
PHE is able to provide this information by clinical commissioning groups (CCGs) and acute trusts.
Table 1 details counts/rates of total MRSA bacteraemia reported by Havering, Barking and Redbridge University hospitals trust and Table 2 lists counts/rates of MRSA bacteraemia attributed to Havering CCG over the last three financial years.
It is important to note that MRSA bacteraemia cases are reported by the acute trust whose laboratory processes the specimen and that this may not always reflect where the bacteraemia was acquired. Counts/rates for total MRSA bacteraemia reported in other CCGs and acute trusts in England is attached and can be found on the gov.uk website:
https://www.gov.uk/government/statistics/mrsa-bacteraemia-annual-data
PHE is working, with partner organisations, to address antimicrobial resistance through the implementation of the ‘UK Five Year Antimicrobial Resistance Strategy’1.
Table 1: Financial year counts and rates of total MRSA bacteraemia reported by Havering, Barking & Redbridge University hospitals (FY 2012/13 to FY 2014/15)
FY 2012/13 | FY 2013/14 | FY 2014/15 | |||||
Trust Code | Trust Name | MRSA bacteraemia reports | MRSA bacteraemia rate per 100,000 bed days | MRSA bacteraemia reports | MRSA bacteraemia rate per 100,000 bed days | MRSA bacteraemia reports | MRSA bacteraemia rate per 100,000 bed days |
England Total | 924 | 2.7 | 862 | 2.5 | 801 | 2.3 | |
RF4 | Barking, Havering and Redbridge University Hospitals | 17 | 4.7 | 10 | 2.9 | 13 | 3.7 |
Source: PHE July 2015 annual publication of surveillance data
Notes:
Bed days were calculated using KH03 data for the stated period. The average daily bed occupancy for the Trust quoted has been multiplied by the number of days in the time period. Rate per 100,000 bed days is calculated as follows:
Calculation of rate (per 100,000 bed days) = [Number of MRSA bacteraemia reports from the trust for the time period divided by Average daily bed occupancy multiplied by Number of days in the time period] multiplied by 100,000
NB: Included KH03 data are as of April 2015. KH03 data for January to March 2015 were not available at this time. Data for the same quarter last year (January to March 2014) has been used in FY 2014/15 bed day calculation.
Table 2: Financial year counts and rates of MRSA bacteraemia attributed to Havering CCG (FY 2012/13 to FY 2014/15)
FY 2012/13 | FY 2013/14 | FY 2014/15 | |||||
CCG Code | CCG Name | Total attributed MRSA bacteraemia specimens | MRSA bacteraemia rate per 100,000 population | Total attributed MRSA bacteraemia specimens | MRSA bacteraemia rate per 100,000 population | Total attributed MRSA bacteraemia specimens | MRSA bacteraemia rate per 100,000 population |
England Total | 924 | 1.7 | 862 | 1.6 | 801 | 1.5 | |
08F | Havering | 9 | 3.8 | 6 | 2.5 | 6 | 2.5 |
Source: PHE July 2015 annual publication of surveillance data
Notes: CCG Populations are based upon Office for National Statistics (ONS) Mid-Year Population Estimates (2011 Census based). The relevant rate per 100,000 population was calculated as follows:
Calculation of rate (per 100,000 bed days) = [Number of MRSA bacteraemia reports from that CCG for the given time period divided by CCG level population estimate] multiplied by 100,000
NB: Included population data are as of April 2015. 2014 population estimates were not available at this time. 2013 population estimate data has been used as a proxy for the FY 2014/15 population.
To ask Her Majesty’s Government what action they are taking to protect public health following the discovery of a strain of MRSA in pork products sold in British supermarkets, which is linked to the overuse of powerful antibiotics in intensive farm production.
To ask Her Majesty’s Government what action they are taking to protect public health following the discovery of a strain of MRSA in pork products sold in British supermarkets, which is linked to the overuse of powerful antibiotics in intensive farm production.
Livestock-associated meticillin resistant Staphylococcus aureus (LA-MRSA) has been found worldwide and is not the same as the MRSA strains that normally cause healthcare-associated infections. If meat is stored, handled and prepared properly, the risk to people is very low and there are no known cases of people contracting LA-MRSA from eating meat.
The annual progress report and implementation plan for the UK five-year Antimicrobial Resistance Strategy includes the measures on animal health to be taken over the next four years to promote the responsible use of antibiotics. This is attached and available at:
https://www.gov.uk/government/publications/progress-report-on-the-uk-five-year-amr-strategy-2014
Regarding LA-MRSA specifically, there are a number of initiatives to reduce the risk, for example, Public Health England regularly reminds diagnostic laboratories of the need for continued vigilance and ensuring that MRSA isolates are submitted for further tests if there may be an association with farming. In addition, Defra and the Veterinary Medicines Directorate are leading a review of options for increased surveillance, which will be proportionate to the low public health risk. Defra is also considering additional guidance for farmers on how to reduce the risk of importing LA-MRSA into their farm. Furthermore Defra have previously worked with the National Pig Association and recommend that anyone importing breeding pigs and semen to Britain should have them screened for MRSA before importation.
To ask the Secretary of State for Environment, Food and Rural Affairs, pursuant to the Oral Answer of the Minister of State, the hon. Member for Camborne and Redruth of 18 June 2015, Official Report, column 445, what the evidential basis is for the statement that livestock-associated MRSA does not...
To ask the Secretary of State for Environment, Food and Rural Affairs, pursuant to the Oral Answer of the Minister of State, the hon. Member for Camborne and Redruth of 18 June 2015, Official Report, column 445, what the evidential basis is for the statement that livestock-associated MRSA does not...
The most common type of LA-MRSA in Europe belongs to clonal complex 398 (CC398). MRSA CC398 is less virulent and transmissible compared to other strains and is unlikely to pass from person to person and become endemic in the human population.
However studies from various countries in continental Europe have demonstrated that in limited circumstances it is possible for MRSA CC398 to be transmitted from animals to people. This tends to be constrained to those who have regular contact with livestock that are carrying the bacteria, in particular pigs.
To ask the Secretary of State for Environment, Food and Rural Affairs, what steps her Department has taken to investigate the implications for human health of the appearance of antibiotic resistant strains of MRSA in pig meat.
To ask the Secretary of State for Environment, Food and Rural Affairs, what steps her Department has taken to investigate the implications for human health of the appearance of antibiotic resistant strains of MRSA in pig meat.
The Advisory Committee on the Microbiological Safety of Food (ACMSF) sub-group on antimicrobial resistance (AMR) has been considering an assessment of the risk to consumers from MRSA in the food chain. Based on current evidence, the risk of contracting MRSA through consumption of foodstuffs is considered to be very low. This will be kept under review. Food Standards Agency food hygiene advice remains the same, i.e. that foodstuffs should be stored appropriately, handled hygienically and meat should be cooked thoroughly.
To ask the Minister for the Cabinet Office how many deaths occurred in 2012 in hospitals in England as a result of MRSA bacteraemia; and how many deaths in total are estimated to have occurred in hospitals in England during the same period.
[151061]
To ask the Minister for the Cabinet Office how many deaths occurred in 2012 in hospitals in England as a result of MRSA bacteraemia; and how many deaths in total are estimated to have occurred in hospitals in England during the same period.
[151061]
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the authority to reply.
Letter from Glen Watson, dated March 2013:
As Director General for the Office for National Statistics, I have been asked to reply to your recent question to the Secretary of State for Health asking how many deaths occurred in 2012 in hospitals in England as a result of MRSA bacteraemia; and how many deaths in total are estimated to have occurred in hospitals in England during the same period. [151061]
In 2011 (the latest available year) there were 53 deaths in hospitals in England where the underlying cause was MRSA and a further 279 where MRSA was shown on the death certificate as a contributory factor. In the same period, there were 230,819 deaths in hospitals in England.1
Further information on deaths involving MRSA is available at the link below. The next edition of the MRSA bulletin, based on 2012 data, is due to be published in August 2013.
http://www.ons.gov.uk/ons/rel/subnational-health2/deaths-involving-mrsa/2007-to-2011/index.html
Annual report of the Chief Medical Officer. Volume Two, 2011: infections and the rise of antimicrobial resistance. 154 p.
Annual report of the Chief Medical Officer. Volume Two, 2011: infections and the rise of antimicrobial resistance. 154 p.
Table showing numbers of cases of MRSA bacteraemia, Clostridium difficile (CDI), and MSSA bacteraemia for England, by NHS Trust, April 2009 to March 2012. 17 p.
Table showing numbers of cases of MRSA bacteraemia, Clostridium difficile (CDI), and MSSA bacteraemia for England, by NHS Trust, April 2009 to March 2012. 17 p.
To ask the Secretary of State for Health how many patients contracted (a) MRSA and (b) other hospital-acquired infections in NHS hospitals in each NHS hospital trust in England and Wales in each of the last three years.
[131612]
To ask the Secretary of State for Health how many patients contracted (a) MRSA and (b) other hospital-acquired infections in NHS hospitals in each NHS hospital trust in England and Wales in each of the last three years.
[131612]
Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections and C. difficile infections are at their lowest levels since mandatory surveillance began. Compared to the 12 months to May 2010, the latest annual data show that MRSA bloodstream infections have fallen by 48% and C. difficile infections by 38%.
Data on health care associated infections in Wales are collated and published by the Welsh Healthcare Associated Infection Programme. Information on all health care associated infections covering England is not collected routinely by the Health Protection Agency. However, the agency does collect data on specific health care associated infections in England, such as MRSA bacteraemia, Clostridium difficile infection, and Methicillin sensitive Staphylococcus aureus bacteraemia, that are detected and reported by an acute NHS Trust laboratory.
The information on these infections has been placed in the Library.
To ask the Secretary of State for Health whether he has any plans to encourage further research into the use of DNA sequencing to prevent outbreaks of MRSA.
[130001]
To ask the Secretary of State for Health whether he has any plans to encourage further research into the use of DNA sequencing to prevent outbreaks of MRSA.
[130001]
The Department's National Institute for Health Research (NIHR) is jointly funding the UKCRC (UK Clinical Research Collaboration) Translational Infection Research Initiative with other UKCRC partners. Under this initiative, two consortia are studying the use of genome sequencing in infection control.
The Modernising Medical Microbiology Consortium aims to exploit recent advances in sequencing the genomes of bacterial and viral pathogens of public health concern, to improve and speed up their classification and identification. The NIHR Oxford Biomedical Research Centre is a partner in the consortium. The work of the consortium includes a study, hosted by the NIHR Clinical Research Network, establishing how new strain typing and database technologies can be optimally integrated into microbiology service and research—to track and identify outbreaks in Staphylococcus aureus and other pathogens.
The Cambridge Translational Microbiology Consortium aims to bring rapid microbial genome sequencing into the heart of the diagnostic microbiology laboratory, and has an initial focus on Methicillin-resistant Staphylococcus aureus (MRSA).
In addition, the NIHR Centre for Health Protection Research has a current project on development of a whole genome sequence-based tool to track MRSA transmission in the United Kingdom.
To ask the Secretary of State for Health how many cases of MRSA have been reported at Queen's Hospital, Romford since 2002.
[130181]
To ask the Secretary of State for Health how many cases of MRSA have been reported at Queen's Hospital, Romford since 2002.
[130181]
The information is not available in the format requested. Information is only held by trust and is only available from April 2008. Queen's Hospital Romford opened in 2006 and is part of Barking, Havering and Redbridge University Hospitals NHS Trust (BHRT).
The numbers of Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia episodes reported at BHRT for the years available is collected by financial year and is shown in the following table:
| Trust
apportioned MRSA bacteraemia reports by financial
year | |
| Number | |
| 2008-09 | 20 |
| 2009-10 | 19 |
| 2010-11 | 15 |
| 2011-12 | 10 |
| Note: The data represents cases of MRSA bacteraemia thought to have acquired within the Trust during the present admission. Source: Health Protection Agency |
To ask the Secretary of State for Environment, Food and Rural Affairs what testing her Department has undertaken on levels of MRSA in (a) poultry farms and (b) chicken and turkey products on sale to the public.
[111361]
To ask the Secretary of State for Environment, Food and Rural Affairs what testing her Department has undertaken on levels of MRSA in (a) poultry farms and (b) chicken and turkey products on sale to the public.
[111361]
Staphylococcus aureus recovered from poultry during laboratory examinations of clinical material at AHVLA Regional Laboratories and subjected to susceptibility testing are examined to determine whether or not they are MRSA. No MRSA have been detected in poultry, although the numbers of isolates examined each year is relatively low.
The Food Standards Agency conducted a UK-wide survey between May 2007 and September 2008 to determine Campylobacter and Salmonella prevalence on fresh chicken at retail. This survey did not include any testing of levels of MRSA in the chicken samples collected. The Food Standards Agency has not conducted any other testing of MRSA in chicken and turkey products on sale to the public.
To ask Her Majesty’s Government what assessment they have made of the progress towards eliminating methicillin-resistant staphylococcus aureus (MRSA) infections in hospitals.
To ask Her Majesty’s Government what assessment they have made of the progress towards eliminating methicillin-resistant staphylococcus aureus (MRSA) infections in hospitals.
To ask the Secretary of State for Health what steps are being taken to protect public health from methicillin-resistant Staphylococcus aureus.
To ask the Secretary of State for Health what steps are being taken to protect public health from methicillin-resistant Staphylococcus aureus.
To ask the Secretary of State for Health whether he intends to bring forward legislative proposals to reduce the incidence of MRSA in milk.
To ask the Secretary of State for Health whether he intends to bring forward legislative proposals to reduce the incidence of MRSA in milk.
Tables showing number and percentage of deaths in care homes where a) MRSA b) C. difficile c) malnutrition d) dehydration was either the underlying cause of death or mentioned anywhere on the death certificate, 1997-2009 and the number of deaths where e) MRSA and f) C. difficile were the underlying cause of death or mentioned anywhere on the death certificate for local authority and non-local authority care homes, 1997-2009. 8 p.
Tables showing number and percentage of deaths in care homes where a) MRSA b) C. difficile c) malnutrition d) dehydration was either the underlying cause of death or mentioned anywhere on the death certificate, 1997-2009 and the number of deaths where e) MRSA and f) C. difficile were the underlying...
To ask the Secretary of State for Environment, Food and Rural Affairs when (a) she and (b) other Ministers in her Department were first informed of the discovery by researchers from the university of Cambridge of a new strain of MRSA in milk from a British herd; and what steps...
To ask the Secretary of State for Environment, Food and Rural Affairs when (a) she and (b) other Ministers in her Department were first informed of the discovery by researchers from the university of Cambridge of a new strain of MRSA in milk from a British herd; and what steps...
Tables showing number and percentage of deaths in care homes where a) MRSA b) C. difficile c) malnutrition d) dehydration was either the underlying cause of death or mentioned anywhere on the death certificate, 1997-2009 and the number of deaths where e) MRSA and f) C. difficile were the underlying cause of death or mentioned anywhere on the death certificate for local authority and non-local authority care homes, 1997-2009. 7 p.
Tables showing number and percentage of deaths in care homes where a) MRSA b) C. difficile c) malnutrition d) dehydration was either the underlying cause of death or mentioned anywhere on the death certificate, 1997-2009 and the number of deaths where e) MRSA and f) C. difficile were the underlying...
I. Table showing MRSA bloodstream infections in Berkshire NHS Trusts from 2001/02 to 2009/10. II. Table showing surgical site infections in Berkshire NHS Trusts, April 2004 to 2010. III. Table showing clostridium difficile infections in Berkshire NHS Trusts, 2004 to 2010.
I. Table showing MRSA bloodstream infections in Berkshire NHS Trusts from 2001/02 to 2009/10. II. Table showing surgical site infections in Berkshire NHS Trusts, April 2004 to 2010. III. Table showing clostridium difficile infections in Berkshire NHS Trusts, 2004 to 2010.
To ask the Secretary of State for Health what assessment he has made of the capacity of methods of screening against the MRSA bacterium used by NHS hospitals to detect new strains of the infection; and if he will make a statement.
To ask the Secretary of State for Health what assessment he has made of the capacity of methods of screening against the MRSA bacterium used by NHS hospitals to detect new strains of the infection; and if he will make a statement.
To ask the Secretary of State for Health what progress has been made on licensing for use in the NHS of the Defence Science and Technology Laboratory's product BacLite to screen against the MRSA bacterium.
To ask the Secretary of State for Health what progress has been made on licensing for use in the NHS of the Defence Science and Technology Laboratory's product BacLite to screen against the MRSA bacterium.
To ask the Secretary of State for Health what steps he is taking to improve methods of screening against the MRSA bacterium; and if he will make a statement.
To ask the Secretary of State for Health what steps he is taking to improve methods of screening against the MRSA bacterium; and if he will make a statement.
(2) what assessment he has made of the merits of the Defence Science and Technology Laboratory's product BacLite for the detection of the MRSA bacterium; and if he will make a statement.
(2) what assessment he has made of the merits of the Defence Science and Technology Laboratory's product BacLite for the detection of the MRSA bacterium; and if he will make a statement.
To ask the Secretary of State for Defence (1) what steps he is taking to allow the Defence Science and Technology Laboratory's product BacLite, for screening against the MRSA bacterium, to be marketed in the UK;
To ask the Secretary of State for Defence (1) what steps he is taking to allow the Defence Science and Technology Laboratory's product BacLite, for screening against the MRSA bacterium, to be marketed in the UK;
To ask the Secretary of State for Health what methods of screening against the MRSA bacterium hospitals use; what assessment he has made of the effectiveness of such methods; and if he will make a statement.
To ask the Secretary of State for Health what methods of screening against the MRSA bacterium hospitals use; what assessment he has made of the effectiveness of such methods; and if he will make a statement.
To ask the Secretary of State for Health how many cases of MRSA infection were identified in NHS facilities in 2010.
To ask the Secretary of State for Health how many cases of MRSA infection were identified in NHS facilities in 2010.
To ask the Secretary of State for Health what steps he is taking to reduce the number of cases of MRSA.
To ask the Secretary of State for Health what steps he is taking to reduce the number of cases of MRSA.
To ask the Secretary of State for Health how many (a) deaths from and (b) cases of (i) clostridium difficile and (ii) MRSA there have been in each region in each of the last three years.
To ask the Secretary of State for Health how many (a) deaths from and (b) cases of (i) clostridium difficile and (ii) MRSA there have been in each region in each of the last three years.
| Table 1. Number of deaths where methicillin-resistant Staphylococcus aureus (MRSA)¹ and Clostridium difficile (C. difficile)² was mentioned on the death certificate, government office regions in England, 2007-09³,4 | ||||||
|---|---|---|---|---|---|---|
| Deaths (persons) | ||||||
| MRSA | C. difficile | |||||
| Government office region | 2007 | 2008 | 2009 | 2007 | 2008 | 2009 |
| North East | 85 | 88 | 53 | 328 | 347 | 311 |
| North West | 199 | 171 | 99 | 1,010 | 980 | 733 |
| Yorkshire and The Humber | 130 | 105 | 68 | 510 | 486 | 298 |
| East Midlands | 116 | 98 | 65 | 823 | 502 | 339 |
| West Midlands | 202 | 147 | 69 | 1,255 | 771 | 440 |
| East of England | 192 | 105 | 68 | 1,035 | 465 | 330 |
| London | 174 | 133 | 98 | 1,001 | 534 | 289 |
| South East | 224 | 167 | 118 | 1,080 | 750 | 481 |
| South West | 195 | 123 | 80 | 874 | 630 | 329 |
| ¹ Identified using the methodology described in Office for National Statistics: Statistical Bulletin: Deaths involving MRSA: England and Wales, 2009. Available at: | ||||||
| www.statistics.gov.uk/pdfdir/mrsa0810.pdf | ||||||
| ² Identified using the methodology described in Office for National Statistics: Statistical Bulletin: Deaths involving Clostridium difficile: England and Wales, 2009. Available at: | ||||||
| www.statistics.gov.uk/pdfdir/cdif0810.pdf | ||||||
| ³ Based on boundaries as of 2010. | ||||||
| 4 Figures are for deaths registered in each calendar year. |
| Table 2. Number of methicillin-resistant Staphylococcus aureus (MRSA)¹ bloodstream infections and Clostridium difficile (C. difficile)² infections in acute NHS trusts by government office region in England, 2007-09³,4 | ||||||
|---|---|---|---|---|---|---|
| Infections | ||||||
| MRSA | C. difficile | |||||
| Government office region | 2007 | 2008 | 2009 | 2007 | 2008 | 2009 |
| North East | 302 | 188 | 84 | 3,379 | 2,706 | 1,873 |
| North West | 670 | 419 | 303 | 9,574 | 6,722 | 4,909 |
| Yorkshire and The Humber | 519 | 356 | 226 | 5,156 | 4,091 | 2,463 |
| East Midlands | 254 | 187 | 138 | 3,691 | 2,475 | 1,957 |
| West Midlands | 511 | 307 | 161 | 7,071 | 4,088 | 3,065 |
| East of England | 333 | 213 | 146 | 5,573 | 2,818 | 2,265 |
| London | 823 | 579 | 409 | 7,270 | 4,326 | 3,011 |
| South East | 586 | 395 | 257 | 7,616 | 5,003 | 3,538 |
| South West | 453 | 291 | 174 | 6,168 | 3,866 | 2,523 |
| ¹ Figures for the number of infections are provided by the Health Protection Agency (HPA). Infections are identified using the methodology described in the HPA report: Healthcare-Associated Infections and Antimicrobial Resistance: 2009/10. Available at: | ||||||
| www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1281954479045 | ||||||
| ² The number of Clostridium difficile infections is given for people aged two years and over. | ||||||
| ³ Based on HPA regions which are equivalent to Government office regions. | ||||||
| 4 Figures are for infections in each financial year. |
To ask the Secretary of State for Health what steps his Department is taking to reduce the incidence of MRSA.
To ask the Secretary of State for Health what steps his Department is taking to reduce the incidence of MRSA.
To ask the Secretary of State for Health what progress has been made towards meeting his Department's 2011 deadline for the screening of non-elective patients for MRSA.
To ask the Secretary of State for Health what progress has been made towards meeting his Department's 2011 deadline for the screening of non-elective patients for MRSA.
To ask the Secretary of State for Health what information his Department collates for the purpose of monitoring rates of MRSA.
To ask the Secretary of State for Health what information his Department collates for the purpose of monitoring rates of MRSA.
To ask the Secretary of State for Health what tests are available to detect (a) MRSA and (b) clostridium difficile infection; and by what means such tests are deployed in the NHS.
To ask the Secretary of State for Health what tests are available to detect (a) MRSA and (b) clostridium difficile infection; and by what means such tests are deployed in the NHS.
To ask the Secretary of State for Health what recent progress has been made on the deployment in the NHS of new tests for (a) MRSA and (b) clostridium difficile; and what steps he is taking to ensure the deployment in the NHS of the most accurate, rapid and cost-effective...
To ask the Secretary of State for Health what recent progress has been made on the deployment in the NHS of new tests for (a) MRSA and (b) clostridium difficile; and what steps he is taking to ensure the deployment in the NHS of the most accurate, rapid and cost-effective...
To ask the Secretary of State for Health (1) what progress has been made towards meeting his Department's 2011 deadline for the screening of non-elective patients for MRSA;
To ask the Secretary of State for Health (1) what progress has been made towards meeting his Department's 2011 deadline for the screening of non-elective patients for MRSA;
(2) how many primary care trusts have started to screen non-elective patients for MRSA in advance of his Department's 2011 deadline for such screening.
(2) how many primary care trusts have started to screen non-elective patients for MRSA in advance of his Department's 2011 deadline for such screening.
To ask Her Majesty's Government what assessment they have made of any connection between animal and human strains of MRSA; and whether they will consider the experience of the Netherlands in that matter.
To ask Her Majesty's Government what assessment they have made of any connection between animal and human strains of MRSA; and whether they will consider the experience of the Netherlands in that matter.
Lords statement on hospital trusts in Essex and patient safety in the NHS.
Lords statement on hospital trusts in Essex and patient safety in the NHS.
My Lords, the Minister has on a number of occasions used the phrase "patient safety" in the context of this Statement and the questions on it. Is she aware of the considerable concern, indeed alarm, in Suffolk, where I live, at reports that the emergency coronary facilities in Ipswich Hospital...
My Lords, the Minister has on a number of occasions used the phrase "patient safety" in the context of this Statement and the questions on it. Is she aware of the considerable concern, indeed alarm, in Suffolk, where I live, at reports that the emergency coronary facilities in Ipswich Hospital...
My Lords, with the leave of the House, I would like to repeat a Statement made in the other place by my right honourable friend the Secretary of State. "With your permission, Mr Speaker, I wish to make a Statement on patient safety in the NHS. Last week, the regulatory...
My Lords, with the leave of the House, I would like to repeat a Statement made in the other place by my right honourable friend the Secretary of State. "With your permission, Mr Speaker, I wish to make a Statement on patient safety in the NHS. Last week, the regulatory...
I thank the noble Earl and the noble Baroness for their remarks. I shall try to work my way through the questions that we are addressing this evening. The noble Earl asked when Ministers become aware of these matters. He asked me exactly the same question when we discussed these...
I thank the noble Earl and the noble Baroness for their remarks. I shall try to work my way through the questions that we are addressing this evening. The noble Earl asked when Ministers become aware of these matters. He asked me exactly the same question when we discussed these...
My Lords, I, too, am grateful to the Minister for repeating the Statement made in another place earlier. Before turning to the substance of that, I also wish to acknowledge the tremendous amount of very high-quality work done in most hospitals and trusts throughout the United Kingdom. It is always...
My Lords, I, too, am grateful to the Minister for repeating the Statement made in another place earlier. Before turning to the substance of that, I also wish to acknowledge the tremendous amount of very high-quality work done in most hospitals and trusts throughout the United Kingdom. It is always...
My Lords, it is certainly true that I am not briefed on the issue. Obviously, patient safety is at the heart of the work that we do, and recent surveys show that 93 per cent of patients rate their overall experience as good or excellent. However, I will undertake to...
My Lords, it is certainly true that I am not briefed on the issue. Obviously, patient safety is at the heart of the work that we do, and recent surveys show that 93 per cent of patients rate their overall experience as good or excellent. However, I will undertake to...
My Lords, the House will be grateful to the Minister for repeating the Statement. The fact that positively glares at us as we listen to this very disturbing announcement is that the deficiencies evident at these two hospitals are not newly discovered findings. They have been known about for many...
My Lords, the House will be grateful to the Minister for repeating the Statement. The fact that positively glares at us as we listen to this very disturbing announcement is that the deficiencies evident at these two hospitals are not newly discovered findings. They have been known about for many...
To ask the Secretary of State for Health what the rate of (a) clostridium difficile and (b) MRSA infection in (i) Bassetlaw Primary Care Trust and (ii) Nottinghamshire County Teaching Primary Care Trust was in each of the last three years for which figures are available.
To ask the Secretary of State for Health what the rate of (a) clostridium difficile and (b) MRSA infection in (i) Bassetlaw Primary Care Trust and (ii) Nottinghamshire County Teaching Primary Care Trust was in each of the last three years for which figures are available.
| Clostridium difficile | ||
|---|---|---|
| Number of cases | Rate per 100,000 population | |
| Bassetlaw PCT | ||
| 2007-08 | 52 | 47.6 |
| 2008-09 | 49 | 44.8 |
| Nottinghamshire County PCT | ||
| 2007-08 | 820 | 127 |
| 2008-09 | 452 | 70 |
| Source: | ||
| Health Protection Agency |
| MRSA bacteraemia | ||
|---|---|---|
| Number of cases | Rate per 100,000 population | |
| Sherwood Forest Hospitals NHS Foundation Trust | ||
| 2006-07 | 44 | 1.66 |
| 2007-08 | 36 | 1.43 |
| 2008-09 | 31 | 1.24 |
| Doncaster and Bassetlaw NHS Foundation Trust | ||
| 2006-07 | 26 | 0.77 |
| 2007-08 | 26 | 0.77 |
| 2008-09 | 13 | 0.39 |
| Notes: | ||
| 1. No acute trust headquarters are located in Bassetlaw PCT. However, Sherwood Forest Hospitals NHS Foundation Trust is located in Nottinghamshire Country Teaching PCT. Doncaster and Bassetlaw NHS Foundation Trust is located in Doncaster PCT. | ||
| 2. Services at Doncaster and Bassetlaw NHS Foundation Trust are mainly commissioned by Doncaster PCT. | ||
| Source: | ||
| Health Protection Agency |
To ask Her Majesty's Government which hospital trusts in 2008–09 did not meet national targets for (a) accident and emergency four-hour maximum waiting times, (b) 18 weeks overall waiting time for treatment, and (c) methicillin resistant staphylococcus aureus; and which of those trusts did not meet any of those targets...
To ask Her Majesty's Government which hospital trusts in 2008–09 did not meet national targets for (a) accident and emergency four-hour maximum waiting times, (b) 18 weeks overall waiting time for treatment, and (c) methicillin resistant staphylococcus aureus; and which of those trusts did not meet any of those targets...
Documents relating to Department of Health research regarding Mid Staffordshire General Hospitals NHS Trust's application for foundation trust status. 53 p.
Documents relating to Department of Health research regarding Mid Staffordshire General Hospitals NHS Trust's application for foundation trust status. 53 p.
To ask the Secretary of State for Health how many cases of MRSA infection in Milton Keynes have been reported to his Department in each year since 1997.
To ask the Secretary of State for Health how many cases of MRSA infection in Milton Keynes have been reported to his Department in each year since 1997.
| Milton Keynes General Hospital NHS Trust | |
|---|---|
| April to March each year | Number of cases of bloodstream infections caused by MRSA |
| 2001-02 | 9 |
| 2002-03 | 13 |
| 2003-04 | 7 |
| 2004-05 | 11 |
| 2005-06 | 23 |
| 2006-07 | 19 |
| 2007-08 | 11 |
| 2008-09 | 14 |
(2) how many cases of MRSA in Luton and Dunstable Hospital have been reported to his Department in each year since 1997; and if he will make a statement.
(2) how many cases of MRSA in Luton and Dunstable Hospital have been reported to his Department in each year since 1997; and if he will make a statement.
| Number of cases of bloodstream infections caused by MRSA | ||
|---|---|---|
| April to March each year | East of England | Luton and Dunstable Foundation Trust |
| 2001-02 | 662 | 22 |
| 2002-03 | 607 | 28 |
| 2003-04 | 678 | 21 |
| 2004-05 | 725 | 19 |
| 2005-06 | 678 | 32 |
| 2006-07 | 529 | 21 |
| 2007-08 | 333 | 15 |
To ask the Secretary of State for Health (1) how many cases of MRSA in the East of England region have been reported to his Department in each year since 1997; and if he will make a statement;
To ask the Secretary of State for Health (1) how many cases of MRSA in the East of England region have been reported to his Department in each year since 1997; and if he will make a statement;
| Number of cases of bloodstream infections caused by MRSA | ||
|---|---|---|
| April to March each year | East of England | Luton and Dunstable Foundation Trust |
| 2001-02 | 662 | 22 |
| 2002-03 | 607 | 28 |
| 2003-04 | 678 | 21 |
| 2004-05 | 725 | 19 |
| 2005-06 | 678 | 32 |
| 2006-07 | 529 | 21 |
| 2007-08 | 333 | 15 |
Our NHS, our future. 58 p.
Our NHS, our future. 58 p.
To ask the Secretary of State for Health (1) whether personal anti-microbial products are supplied by the NHS to patients identified through screening to be carrying MRSA;
To ask the Secretary of State for Health (1) whether personal anti-microbial products are supplied by the NHS to patients identified through screening to be carrying MRSA;
(2) what steps he expects NHS hospitals to take to decolonise patients found through screening to be carrying MRSA; and if he will make a statement;
(2) what steps he expects NHS hospitals to take to decolonise patients found through screening to be carrying MRSA; and if he will make a statement;
(3) how many pre-operative patients he expects to be screened by the NHS for MRSA in the next 12 months; what estimate he has made of the cost per patient of such screening; and if he will make a statement.
(3) how many pre-operative patients he expects to be screened by the NHS for MRSA in the next 12 months; what estimate he has made of the cost per patient of such screening; and if he will make a statement.
To ask the Secretary of State for Health pursuant to the answer of 24 March 2009, Official Report, column 225W, on hospital-acquired infections, if he will place in the Library the dataset used to calculate the 65 per cent. reduction in methicillin resistant Staphylococcus aureus against the 2003-04 baseline.
To ask the Secretary of State for Health pursuant to the answer of 24 March 2009, Official Report, column 225W, on hospital-acquired infections, if he will place in the Library the dataset used to calculate the 65 per cent. reduction in methicillin resistant Staphylococcus aureus against the 2003-04 baseline.
To ask Her Majesty's Government what progress is being made to combat healthcare associated infections in National Health Service hospitals.
To ask Her Majesty's Government what progress is being made to combat healthcare associated infections in National Health Service hospitals.
To ask the Secretary of State for Health (1) on what date the UK authorities were informed by Novartis that a staphylococcus aureas bacterial contamination had been found in a sample of the solvent used in meningitis C vaccine outside the UK;
To ask the Secretary of State for Health (1) on what date the UK authorities were informed by Novartis that a staphylococcus aureas bacterial contamination had been found in a sample of the solvent used in meningitis C vaccine outside the UK;
(3) when the Medicines and Healthcare Products Regulatory Agency issued a cascade alert concerning the meningitis C vaccine.
(3) when the Medicines and Healthcare Products Regulatory Agency issued a cascade alert concerning the meningitis C vaccine.
(2) how many samples of meningitis C vaccine have been additionally tested for sterility in the UK following notification by Novartis of contamination of a sample elsewhere than in the UK; and when such tests were (a) begun and (b) completed;
(2) how many samples of meningitis C vaccine have been additionally tested for sterility in the UK following notification by Novartis of contamination of a sample elsewhere than in the UK; and when such tests were (a) begun and (b) completed;
In moving this amendment I shall speak also to Amendment 36, and in doing so bring us to a subject that is particularly close to the Minister’s heart, namely quality accounts. I should say immediately to him that I see considerable potential in the idea of quality accounts. Nothing that...
In moving this amendment I shall speak also to Amendment 36, and in doing so bring us to a subject that is particularly close to the Minister’s heart, namely quality accounts. I should say immediately to him that I see considerable potential in the idea of quality accounts. Nothing that...
We may disagree about when people should gather to review these documents, but I hope that we will have a fair degree of unanimity about who should be involved in the review. The amendment seeks to clarify that the process of review will be meaningful to all involved. It sets...
We may disagree about when people should gather to review these documents, but I hope that we will have a fair degree of unanimity about who should be involved in the review. The amendment seeks to clarify that the process of review will be meaningful to all involved. It sets...
Perhaps I may add just one further bit of clarification on this crucial issue—and it is crucial, actually—which relates also to the point raised here about dignity. The fact is that there is now an extremely detailed patient survey: direct responses by patients about their treatment on a whole range...
Perhaps I may add just one further bit of clarification on this crucial issue—and it is crucial, actually—which relates also to the point raised here about dignity. The fact is that there is now an extremely detailed patient survey: direct responses by patients about their treatment on a whole range...
I am grateful for that intervention from my noble friend. I have no doubt that the noble Baroness, Lady Young, will have a lot to say about this as it is in the domain of the regulator. As to which ward has MRSA, every organisation has a legally accountable board....
I am grateful for that intervention from my noble friend. I have no doubt that the noble Baroness, Lady Young, will have a lot to say about this as it is in the domain of the regulator. As to which ward has MRSA, every organisation has a legally accountable board....
That may have been Aneurin Bevan’s vision when he said that the echo of a bedpan falling in Wales would be heard in Whitehall. I see the NHS having that accountability at a local level in years to come. I sympathise with what has been said. I can even go...
That may have been Aneurin Bevan’s vision when he said that the echo of a bedpan falling in Wales would be heard in Whitehall. I see the NHS having that accountability at a local level in years to come. I sympathise with what has been said. I can even go...
Amendment 35 35: Clause 6, page 4, line 26, leave out paragraph (d)
Amendment 35 35: Clause 6, page 4, line 26, leave out paragraph (d)
Could the Secretary of State block a quality account before it is made available to the public under Clause 7(5) on the basis that he does not want particular information to be published in that report? I understand that there will be a series of regulations requiring what information can...
Could the Secretary of State block a quality account before it is made available to the public under Clause 7(5) on the basis that he does not want particular information to be published in that report? I understand that there will be a series of regulations requiring what information can...
I have always had a fairly radical view about this. I do not think anyone could work in health or social care without having the attributes of treating people with dignity and respect. If an issue arises, I do not think the quality account is the way for redress, but...
I have always had a fairly radical view about this. I do not think anyone could work in health or social care without having the attributes of treating people with dignity and respect. If an issue arises, I do not think the quality account is the way for redress, but...
I thank the Minister for that reply and for the commitment to this that he emphasised. My noble friend Lady Murphy indicated to me that she has raised these issues before. They are terribly important and have played an enormous part in my life over the past few years, emphasising...
I thank the Minister for that reply and for the commitment to this that he emphasised. My noble friend Lady Murphy indicated to me that she has raised these issues before. They are terribly important and have played an enormous part in my life over the past few years, emphasising...
To seek more clarification, say that a maternity unit in a given area is found to have problems in the quality account, it may well be that the commissioning process is at fault and therefore that maternity department is not able to deliver to the required quality. The poor quality...
To seek more clarification, say that a maternity unit in a given area is found to have problems in the quality account, it may well be that the commissioning process is at fault and therefore that maternity department is not able to deliver to the required quality. The poor quality...
Clause 6: Duty of providers to publish information Amendment 33 33: Clause 6, page 4, line 13, after ““containing”” insert ““(but not limited to)””
Clause 6: Duty of providers to publish information Amendment 33 33: Clause 6, page 4, line 13, after ““containing”” insert ““(but not limited to)””
I thank all noble Lords who contributed to this short debate. I say to the noble Baroness, Lady Young of Old Scone, that although the inclusion of the CQC may look incidental, it was entirely deliberate on our part. For the reasons she outlined, it makes sense for the regulator...
I thank all noble Lords who contributed to this short debate. I say to the noble Baroness, Lady Young of Old Scone, that although the inclusion of the CQC may look incidental, it was entirely deliberate on our part. For the reasons she outlined, it makes sense for the regulator...
Amendments 26 and 28, tabled by the noble Baronesses, Lady Barker and Lady Tonge, propose that the Handbook to the NHS Constitution be reviewed at least every five years, rather than every three years as Clause 4 provides. Amendments 30 and 32 propose that the Secretary of State report on...
Amendments 26 and 28, tabled by the noble Baronesses, Lady Barker and Lady Tonge, propose that the Handbook to the NHS Constitution be reviewed at least every five years, rather than every three years as Clause 4 provides. Amendments 30 and 32 propose that the Secretary of State report on...
It is unfortunate that this is the next amendment. Members of the Committee might think that I have a fixation with five-year plans, but I do not. There is a reason for this amendment. The length of time in which the handbook and the constitution should be reviewed has turned...
It is unfortunate that this is the next amendment. Members of the Committee might think that I have a fixation with five-year plans, but I do not. There is a reason for this amendment. The length of time in which the handbook and the constitution should be reviewed has turned...
Can the Minister clarify the Government’s perception of what have been the Healthcare Commission and Standards for Better Health returns from all these provider trusts? He focused closely on the CQC and the registration criteria. Does he envisage some sort of quality returns at this higher level to the CQC...
Can the Minister clarify the Government’s perception of what have been the Healthcare Commission and Standards for Better Health returns from all these provider trusts? He focused closely on the CQC and the registration criteria. Does he envisage some sort of quality returns at this higher level to the CQC...
I do. The regulator has played an extremely important role in quality improvements and will continue to do so. Anyone who wishes to be involved in quality improvements should be encouraged to be so, whether they are regulators or clinicians working on the front line. This is an inclusive space....
I do. The regulator has played an extremely important role in quality improvements and will continue to do so. Anyone who wishes to be involved in quality improvements should be encouraged to be so, whether they are regulators or clinicians working on the front line. This is an inclusive space....
The role of the Secretary of State is to get that information and to make it available on the NHS Choices website. That information would be made public by the board of the provider. The legislation would ensure that every board publishes its quality accounts locally for accountability and transparency...
The role of the Secretary of State is to get that information and to make it available on the NHS Choices website. That information would be made public by the board of the provider. The legislation would ensure that every board publishes its quality accounts locally for accountability and transparency...
If a PCT identifies a mistake in the information in a quality account or if the CQC identifies an issue in its indicators, the quality account has to be changed. If a provider does not wish to embarrass itself by publishing inaccurate information, we encourage it to check that information...
If a PCT identifies a mistake in the information in a quality account or if the CQC identifies an issue in its indicators, the quality account has to be changed. If a provider does not wish to embarrass itself by publishing inaccurate information, we encourage it to check that information...
I am sorry that I did not bring this up earlier. Patient experience is not purely information captured from patients; it is captured from their families, their carers and other people involved in their care. Patients and their relatives will have other ways in which they can capture that information....
I am sorry that I did not bring this up earlier. Patient experience is not purely information captured from patients; it is captured from their families, their carers and other people involved in their care. Patients and their relatives will have other ways in which they can capture that information....
I hope the Committee will forgive me for descending into the realm of drafting detail, but Clause 7(3) contains the word ““notify”” as a plural verb applying to the subject of the sentence. Both the CQC and an SHA are singular entities in statute law. If they are separated, as...
I hope the Committee will forgive me for descending into the realm of drafting detail, but Clause 7(3) contains the word ““notify”” as a plural verb applying to the subject of the sentence. Both the CQC and an SHA are singular entities in statute law. If they are separated, as...
Clause 7: Supplementary provision about the duty Amendment 40 40: Clause 7, page 5, line 7, leave out ““notify”” and insert ““notifies””
Clause 7: Supplementary provision about the duty Amendment 40 40: Clause 7, page 5, line 7, leave out ““notify”” and insert ““notifies””